Spondyloarthritis

Among patients with axial spondyloarthritis, disease activity surpassed other ‘key drivers’ such as enthesitis, gender and spinal mobility in explaining disability, according to data published in Arthritis Care & Research.

Tight control and treat-to-target, although cost-effective, are not superior to usual care for improving ASAS-HI scores in patients with axial spondyloarthritis, according to a speaker at ACR Convergence 2020.

Artificial neural networks can assess and detect radiographic sacroiliitis, helping physicians to diagnose and classify axial spondyloarthritis, according to data presented at the American College of Rheumatology 2020 Annual Meeting.

The 2020 Rheumatology Winter Clinical Symposium will feature presentations intended to foster active discussion between those on the dais and those in attendance. The meeting, which is in its 13th year, will take place February 12 to 15, at the Wailea Beach Marriott in Maui, Hawaii.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

The FDA has extended approval for ixekizumab injection 80 mg/mL to treat adults with ankylosing spondylitis – or radiographic axial spondyloarthritis - according to an Eli Lilly press release.